Homozygous familial hypercholesterolemia

References

• Rocha VZ, Chacra AP, Salgado W et al. Extensive xanthomata and severe subclinical atherosclerosis in homozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 61(21), 2193 (2013).
   Google Scholar
• Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223(2), 262–268 (2012). ▪▪ Review of the current status of diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH).
   Google Scholar
• Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168(1), 1–14 (2003).
   Google Scholar
• Arora G, Fraser CD, Kearney DL, Vincent JA. Severe supravalvar aortic stenosis in familial homozygous hypercholesterolemia. Pediatr. Cardiol. 27(2), 282–285 (2006).
   Google Scholar
• Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 337, A1095 (2008).
   Google Scholar
• Kotze MJ, Peeters AV, Loubser O et al. Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Clin. Genet. 54(1), 74–78 (1998).
   Google Scholar
• Feingold KR. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J. Lipid Res. 48(12), 2531–2546 (2007).
   Google Scholar
• Aliev G, Castellani RJ, Petersen RB, Burnstock G, Perry G, Smith MA. Pathobiology of familial hypercholesterolemic atherosclerosis. J. Submicrosc. Cytol. Pathol. 36(3–4), 225–240 (2004).
   Google Scholar
• Marais AD, Raal FJ, Stein EA et al. A dosetitration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197(1), 400–406 (2008).
   Google Scholar
• Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469–2475 (2002).
   Google Scholar
• Thompson GR, Maher VM, Matthews S et al. Familial hypercholesterolaemia regression study: a randomised trial of low‑density‑lipoprotein apheresis. Lancet 345(8953), 811–816 (1995). ▪ Original trial of apheresis in reducing coronary mean lumen diameter progression in HoFH.
   Google Scholar
• Thompson GR. The evidence‑base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler. Suppl. 14(1), 67–70 (2013). ▪▪ Complete review of the efficacy data on apheresis in HoFH.
   Google Scholar
• Thompson GR, Catapano A, Saheb S et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 21(6), 492–498 (2010). ▪▪ Clinical selection and treatment goals for apheresis in HoFH.
   Google Scholar
• Wierzbicki AS, Hardman TC, Viljoen A. New lipid‑lowering drugs: an update. Int. J. Clin. Pract. 66(3), 270–280 (2012). ▪ Overview of new lipid-lowering therapies in development.
   Google Scholar
• Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr. Vasc. Pharmacol. 7(3), 277–286 (2009).
   Google Scholar
• Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356(2), 148–156 (2007).
   Google Scholar
• Raal FJ. Lomitapide for homozygous familial hypercholesterolaemia. Lancet 381(9860), 7–8 (2013). ▪ Clinical trial of lomitapide therapy in HoFH, including patients on apheresis.
   Google Scholar
• Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double‑blind, placebocontrolled trial. Lancet 375(9719), 998–1006 (2010). ▪ Clinical trial of mipomersen in patients with HoFH.
   Google Scholar
• Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid‑lowering therapy. Circulation 124(20), 2202–2207 (2011). ▪▪ Morbidity and mortality benefits of treating HoFH with current drug therapies.
   Google Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, A2423 (2008).
   Google Scholar